Emergent BioSolutions | EBS - Lucro Operacional





Lucro Operacional Alterar Data
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Akebia Therapeutics USD -5.45M 9.4M 2025-12
ALKERMES USD -65.93M 17.65M 2026-06
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Amarin USD -2.26M 564K 2025-12
ANI Pharmaceuticals USD 39.84M 1.13M 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Coherus Biosciences USD -39.08M 3.65M 2025-12
Emergent BioSolutions USD -218M 69.9M 2023-06
Exelixis USD 248.41M 2.93M 2026-06
Glaxosmithkline GBP 2.29B 3.08M 2026-03
Heron Therapeutics USD 38K 3.83M 2025-12
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
Ironwood Pharmaceuticals USD 33.22M 7.58M 2024-12
Lexicon Pharmaceuticals USD -14.78M 2.59M 2025-12
Lonza CHF 673M 243M 2025-06
Merck USD 840M 2.72B 2026-06
Moderna USD -815M 573M 2026-06
Myriad Genetics USD -3M 20.3M 2025-12
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
Pacira USD 9.96M 5.33M 2026-06
Pfizer USD 667M 4.32B 2026-06
PTC Therapeutics USD 45.89M 127.51M 2026-03
Sanofi EUR 2.38B 449M 2026-06
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
United Therapeutics USD 330.8M 5M 2026-06
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12